Brought to you by 
AbbVie pays $63bn in cash and stock for Allergan
Jun 2019
Executive Summary
AbbVie Inc. is buying Allergan PLC for an equity value of $63bn in cash and stock. Allergan shareholders will receive $188.24 per share ($120.30 in cash and 0.8660 AbbVie shares (worth $67.94)).
Deal Industry
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Topical Delivery
- Transdermal
- OTC, Consumer
- Specialty Pharmaceuticals
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Acquisition
- Payment Includes Cash
- Includes Contract
- Payment Includes Stock
- Full Acquisition
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AbbVie pays $63bn in cash and stock for Allergan
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice